Organic Growth and Margin Resilience in Focus as Sagility Targets Q2 Print
Sagility India heads into Q2 FY27 results on strong momentum—Q1 clocked 27.6% revenue growth with expanding profitability despite wage headwinds. The Street consensus (Strong Buy, ₹54.50 median target) hinges on sustained client growth and margin defence. Watch for evidence the company can hold its 24–25% EBITDA margin guidance through seasonal Q2.
What to Expect
~₹1,950–2,000 Cr
On-plan run-rate; Q1 was ₹1,963 Cr (+27.6% YoY). Growth trajectory intact if organic expansion holds.
24–25%
FY27 guidance reiterated despite 1.2% wage-inflation headwind. Q1 adjusted EBITDA margin at 24.0%.
~₹210–220 Cr
Q1 PAT ₹217 Cr on 45.6% YoY growth; steady-state PAT likely in range if margins hold and growth moderates slightly.
Net adds in 109-client base
Q1 added 27 clients; CareSeed acquisition complete. Watch for sustained traction in healthcare & BPO.
A strong Q2 would show revenue growth sustaining above 25% YoY, EBITDA margin holding firm at 24%+ despite the seasonal mix, and evidence of continued net client additions. A weak Q2 would signal margin compression below 24% (suggesting wage pressures winning), growth slowing below 20% YoY (execution risk), or flat/negative client adds (competitive pressure in healthcare BPO).
On Track?
Sagility is tracking its FY27 guidance—low double-digit constant-currency revenue growth, 24–25% adjusted EBITDA margin. Q1's 27.6% organic growth came in well ahead of the low double-digit target, and management has publicly reiterated confidence the margin guidance holds despite state wage hikes. The CareSeed acquisition (closed Q1) adds a healthcare analytics/Medicare Advantage module, diversifying the service mix. FY26 closed with a final dividend of ₹0.10/share; the company continues to return capital while investing in acquisitions. No material deviations from the full-year trajectory signal—this is a continuation quarter.
What the Street Says
Since Last Quarter
1 · Board Meeting Scheduled (Oct 22)
BSE intimation confirms Board will meet on 2026-10-22 to consider and approve unaudited Q2 standalone and consolidated results, and dividend recommendation. Routine governance; dividend decision (if any) will signal capital allocation stance.
2 · Management Change: Global General Counsel
Daniel B. Bailey resigned as Global General Counsel effective Oct 2, 2026 (personal reasons). Brian Clayton appointed as replacement. No operational impact flagged; typical C-suite transition. Tenure transition risk: watch for any Q2 guidance commentary around legal/compliance costs.
3 · FY26 Final Dividend Processed (Sep 25)
Final dividend of ₹0.10/share credited to shareholders. Consistent with Q1 FY27 narrative: modest but steady capital returns alongside organic growth investment.
4 · Insider Trading Window Closed (Sep 24)
Sagility closed its trading window per SEBI insider-trading regulations ahead of results. Routine pre-result blackout; no signal.
The Setup
Sagility enters Q2 FY27 on momentum—Q1 delivered 27.6% organic revenue growth and a 46% profit surge on the back of strong client momentum (27 net adds to a 109-client base) and operational leverage, despite state-level wage inflation headwinds in Karnataka and Telangana (1.2% estimated drag). Management has publicly reiterated its FY27 guidance: low double-digit constant-currency growth and 24–25% adjusted EBITDA margin, betting that operational efficiencies and rupee depreciation will offset wage pressure. The Street is overwhelmingly bullish (Strong Buy, ₹54.50 median target), but the margin hold is the real test. Watch for (1) whether organic growth remains above 25% YoY or signals seasonal deceleration, (2) proof that the 24–25% EBITDA margin guidance is achievable under wage inflation, and (3) continued net client adds as evidence the healthcare BPO segment remains competitive. Any surprise miss on margins or growth will reprrice the upside.
Informational and educational content only. Not investment advice.